PCM
VERV

Penserra Capital Management’s Verve Therapeutics VERV Stock Holding History

Penserra Capital Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-8,544
Closed -$113K – 1366
2023
Q3 		$113K Buy
8,544
+1,350
+19% +$21.7K ﹤0.01% 868
2023
Q2 		$134K Buy
7,194
+1,144
+19% +$19.1K ﹤0.01% 890
2023
Q1 		$87K Buy
6,050
+440
+8% +$8.62K ﹤0.01% 789
2022
Q4 		$108K Sell
5,610
-8,109
-59% -$215K ﹤0.01% 798
2022
Q3 		$471K Buy
13,719
+10,819
+373% +$345K 0.01% 444
2022
Q2 		$44K Buy
2,900
+860
+42% +$13.3K ﹤0.01% 929
2022
Q1 		$46K Buy
+2,040
New +$58.3K ﹤0.01% 1029

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Penserra Capital Management's VERV Position: Q4 2023 in Review

Penserra Capital Management sold out of Verve Therapeutics (VERV) in Q4 2023, closing a stake of 8,544 shares — an estimated $113K sold.

Penserra Capital Management first reported a position in VERV in Q1 2022 and held it in 7 quarters. The position peaked at $471K in Q3 2022. 157 funds tracked by Wall St. Rank hold VERV as of Q4 2023.

  • Penserra Capital Management reported no remaining Verve Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Penserra Capital Management sold 8,544 Verve Therapeutics shares in Q4 2023, an estimated $113K.
  • Penserra Capital Management first reported a position in Verve Therapeutics in Q1 2022 and held it in 7 quarters.
  • Penserra Capital Management's Verve Therapeutics position peaked at $471K in Q3 2022.
  • 157 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2023.

Based on Penserra Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.